Literature DB >> 8020661

The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B.

C M Chu1, I S Sheen, Y F Liaw.   

Abstract

BACKGROUND/AIMS: The role of hepatitis C virus in fulminant hepatitis remains controversial and needs further investigation. The aim of this study was to examine the role of hepatitis C virus in fulminant hepatitis in an area with endemic hepatitis A and B.
METHODS: Serological markers of hepatitis C virus were studied in 62 adults from Taiwan with fulminant viral hepatitis.
RESULTS: Of 62 patients, 5 (8.1%) were infected with acute type B hepatitis, 11 (17.7%) were infected with acute non-A, non-B hepatitis, and the remaining 46 (74.2%) were hepatitis B surface antigen (HBsAg) positive but immunoglobulin M (IgM) antibody to hepatitis B core antigen negative. Of the latter, 11 (23.9%) were IgM antibody to hepatitis D virus positive, 16 (34.8%) had high-titered serum hepatitis B virus DNA (> 1000 pg/mL) and were suspected to have hepatitis B virus reactivation, and the other 19 (41.3%) had no identified causes. Serum hepatitis C virus RNA was found in 5 (45.5%) of 11 patients with fulminant non-A, non-B hepatitis, 3 (27.3%) of 11 HBsAg carriers with delta superinfection, and 6 (31.6%) of 19 HBsAg carriers with fulminant hepatitis of undetermined cause.
CONCLUSIONS: Nearly half of fulminant non-A, non-B hepatitis and about 20% of HBsAg carriers with superimposed fulminant hepatitis in Taiwan could be attributed to hepatitis C virus infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020661     DOI: 10.1016/0016-5085(94)90076-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

Review 1.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

2.  Viral superinfection in previously unrecognized chronic carriers of hepatitis B virus with superimposed acute fulminant versus nonfulminant hepatitis.

Authors:  C M Chu; C T Yeh; Y F Liaw
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

Review 3.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

4.  Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic.

Authors:  C M Chu; C T Yeh; C T Chiu; I S Sheen; Y F Liaw
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

Review 5.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

Review 6.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.

Authors:  Rong-Nan Chien
Journal:  Hepatol Int       Date:  2008-04-10       Impact factor: 6.047

8.  Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection.

Authors:  Norio Akuta; Fumitaka Suzuki; Mariko Kobayashi; Akihito Tsubota; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

9.  Acute hepatitis C virus (HCV) infection in chronic carriers of hepatitis B virus (HBV): the impact of underlying active HBV replication on persistence of HCV infection and antibody responses to HCV.

Authors:  C-M Chu; C T Yeh; I S Sheen; Y F Liaw
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

10.  Liver transplantation for acute hepatic failure.

Authors:  Eric T Castaldo; Ravi S Chari
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.